Essential Tremor (ET) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

ET Marketed and Pipeline Drugs Report Overview

Essential tremor (ET) is a neurological disorder that causes involuntary and rhythmic shaking in the hands, head, trunk, voice, or legs. It is one of the most common trembling disorders and is frequently confused with Parkinson’s disease (PD). ET is common among people older than 40, but it can affect people at any age.

The ET marketed and pipeline drugs market research report includes an assessment of the disease, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for ET (SIP).

ET Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for ET marketed drugs are injection and oral. The majority of marketed drugs for ET are oral therapies.

ET Marketed Drugs Analysis, by Routes of Administration, 2023 (%)

For more RoA insights into the ET marketed drugs, download a free report sample

ET Marketed Drugs Segmentation by MoA

The key MoA for ET marketed drugs are receptor antagonists and receptor agonists. The majority of marketed drugs for ET are receptor antagonists in terms of mechanisms of action.

ET Marketed Drugs Analysis, by MoA, 2023 (%)

For more MoA insights into the ET marketed drugs, download a free report sample

ET Pipeline Drugs Segmentation by MoA

The key MoA for ET pipeline drugs are receptor antagonist, protein and peptide inhibitor, transporter inhibitor, and receptor agonist among others. The majority of pipeline drugs for ET are receptor agonists in terms of mechanisms of action.

ET Pipeline Drugs Analysis, by MoA, 2023 (%)

For more MoA insights into the ET pipeline drugs, download a free report sample

ET Pipeline Drugs Segmentation by Routes of Administration

The key routes of administration for ET pipeline drugs are oral, injection, and topical. Of all the ET pipeline drugs, oral is the most common route of administration.

ET Pipeline Drugs Analysis, by Routes of Administration, 2023 (%)

For more RoA insights into the ET pipeline drugs, download a free report sample

ET Pipeline Drugs Segmentation by Molecule Types

The key molecule types for ET pipeline drugs are small molecule and biologic. The ET pipeline mostly comprises small molecules.

ET Pipeline Drugs Analysis, by Molecule Types, 2023 (%)

For more molecule types insights into the ET pipeline drugs, download a free report sample

Top Sponsors in the ET Marketed and Pipeline Drugs Market

Some of the top sponsors in the ET marketed and pipeline drugs market are Sage Therapeutics, Cadent Therapeutics Inc, Jazz Pharmaceuticals plc, and Syracuse university among others.

ET Marketed Drugs Market Report Overview

ET Pipeline Drugs Market Report Overview

Segments Covered in the Report

ET Marketed Drugs Market Routes of Administration Outlook (Number of Products)

• Injection
• Oral

ET Marketed Drugs Market MoA Outlook (Number of Products)

• Receptor Antagonist
• Receptor Agonist

ET Pipeline Drugs Market Routes of Administration Outlook (Number of Products)

• Oral
• Injection
• Topical

ET Pipeline Drugs Market MoA Outlook (Number of Products)

• Receptor Antagonist
• Protein and Peptide Inhibitor
• Transporter Inhibitor
• Receptor Agonist

ET Pipeline Drugs Market Molecule Types Outlook (Number of Products)

• Small Molecule
• Biologic

Scope

GlobalData’s ET Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combine data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the ET Prophylactics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ET Prophylactics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.